Case Study: Cross-Strait Agreement Could Shorten IND Timeframe For Products Entering China (Part 2 of 2)

Global pharmaceutical firms can look no further than across the Taiwan Strait when working to get products approved and launched in China faster.

In Part 1 of this case study, we looked at the impact of the Cross-Strait Medical and Healthcare Cooperation Agreement between Taiwan and China through the example of Taiwan’s Medigen Biotechnology Corp., which initiated a Phase III trial in mainland China based on data from Phase I/II trials in Taiwan. Companies that are able to follow Medigen's lead could potentially skip early clinical trial work in China – and the country's notoriously long IND approval timelines – by using data from Taiwan ([A#28120620015]).

[Editor’s Note: Want to know more about how China is changing the global pharma landscape? Participate in our anonymous survey...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from China

BlissBio Goes Solo On HER2-Targeting ADC After Eisai Exit

 

BlissBio is to single-handedly move BB-1701, its eribulin-containing, HER2-targeting antibody-drug conjugate, into a global pivotal Phase II/III program for HER2-expressing, Enhertu-resistant breast cancer.

US Tariff Overhang Weighs on Chinese API Exports

 

Chinese API exports to the US fell by 24% year-on-year to $255m in May, when the US and China called a truce in a previously escalating trade war.

Chinese Developers Showcase Potentially Differentiated Weight Loss Assets At ADA

 
• By 

Multiple Chinese firms presented at this year’s ADA meeting, with a focus on weight reduction efficacy for mostly early clinical stage assets. While limited information was given on lean mass preservation, several companies are progressing drugs and combos to address this need.

China Signals Restarting IPOs For Unprofitable Biotechs

 

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

More from Focus On Asia

BlissBio Goes Solo On HER2-Targeting ADC After Eisai Exit

 

BlissBio is to single-handedly move BB-1701, its eribulin-containing, HER2-targeting antibody-drug conjugate, into a global pivotal Phase II/III program for HER2-expressing, Enhertu-resistant breast cancer.

Watch This Space: Miltenyi‘s ‘Brain-To-Vein,’ Point-Of-Care CAR-T Efforts In India

 

From a letter of intent with BIRAC sealed at BIO 2025 to supporting Immuneel’s CAR-T efforts and a study for point-of-care manufactured anti-CD19 CAR-T cell therapy, Miltenyi Biotec is moving on multiple fronts in India. The German group also expects to advance its own CAR-T candidates.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.